Bicycle Therapeutics

@Bicycle_tx

Bicycle is pioneering a new class of therapies based on its bicyclic peptide platform. Cambridge, UK & Cambridge, US Twitter guidelines:

Vrijeme pridruživanja: rujan 2015.

Tweetovi

Blokirali ste korisnika/cu @Bicycle_tx

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Bicycle_tx

  1. 4. velj

    We’re looking for a collaborative, passionate Translational Data Scientist to join our team based in Lexington, MA. Learn more about this opportunity to help discover cutting-edge therapies based on our unique Bicycle® technology:

    Poništi
  2. 7. sij

    We’re excited to partner with to develop a new therapeutic candidate, BT7401, a multivalent Bicycle® CD137 agonist and the latest addition to our portfolio of novel IO assets. Read about our collaboration in today’s press release:

    Poništi
  3. 20. pro 2019.

    The Bicycle team is growing! We’re seeking motivated and experienced candidates for open positions in the UK. Visit our website to learn about these exciting roles:

    Poništi
  4. 20. stu 2019.

    We’re delighted to be a highly commended European IPO of the Year at the 2019 ! This distinction recognizes our pioneering IPO, which has allowed us to grow and advance an innovative pipeline based on our novel Bicycle® technology.

    Poništi
  5. 14. stu 2019.

    Powerful science doesn't just happen - it stems from powerful people. Our work to develop novel approaches for treating cancer and other difficult-to-treat diseases is .

    Poništi
  6. 14. stu 2019.

    Today, one of our Senior Scientists will present a poster at on our novel, proprietary small molecule scaffolds, which we use to constrain Bicycles®, conferring many unique properties. Learn about the innovative structure of Bicycles®:

    Poništi
  7. 13. stu 2019.

    We are excited to announce the initiation of a Phase I/II trial for BT5528, a Bicycle® Toxin Conjugate targeting the tumor antigen EphA2 and our first U.S. IND! Read more about this important step for Bicycle:

    Poništi
  8. 8. stu 2019.

    We’re delighted to have been named Best Established Biotech at the 2019 Awards, celebrating innovation and achievement in the life sciences industry. Thank you to the OBN judges for this recognition and to the Bicycle team for getting us to where we are today!

    Poništi
  9. 6. stu 2019.

    We’re at where our CSO, Nick Keen, Ph.D., will deliver an oral presentation on new preclinical data for BT7480, a potent tumor-targeted immune cell agonist and our lead candidate. Find more details here:

    Poništi
  10. 5. stu 2019.

    Bicycle's proprietary and differentiated technology has the potential to impact a broad range of therapeutic areas beyond oncology. Learn more about how we’re exploring the possible far-reaching applicability of our novel platform here:

    Poništi
  11. 31. lis 2019.

    Bicycle is pleased to announce the appointment of Veronica Jordan, Ph.D., an accomplished life science business leader, to our Board of Directors. Read more in our press release:

    Poništi
  12. 29. lis 2019.

    Bicycle welcomes Nigel Crockett, Ph.D., who joins the team as Chief Business Officer. Nigel has a proven track record in business development and brings to Bicycle over 25 years of industry experience. More details in today’s announcement:

    Poništi
  13. 25. lis 2019.

    Interested in joining a team of passionate, driven individuals working tirelessly to translate innovative, proprietary science into transformative medicines? Learn more about current openings at Bicycle:

    Poništi
  14. 23. lis 2019.

    Bicycle's novel science is by new ideas and continuous teamwork. Learn more about the Bicycle team and read perspectives from other current employees:

    Poništi
  15. 22. lis 2019.

    We’ve expanded our collaboration with to include Oxford's Learn more about this project to discover new therapies enabled by the differentiated properties of Bicycles® that could transform the treatment of dementia: /bit.ly/365AXD4

    Poništi
  16. 16. lis 2019.

    We look forward to presenting new translational data on BT1718 describing patient selection for our Phase IIa study & preclinical data from our other Bicycle® Toxin Conjugates at the AACR-NCI-EORTC 2019 meeting. Read more about our poster presentations:

    Poništi
  17. 8. lis 2019.

    Our CSO, Nick Keen, Ph.D., will be at to deliver a keynote presentation on the power our Bicycle® Toxin Conjugates could have to solve therapeutic challenges unaddressed by other treatment modalities. Learn about our programs here:

    Poništi
  18. 7. lis 2019.

    Check out Bicycle’s feature in today’s article on biotechs founded on winning technology!

    Poništi
  19. 4. lis 2019.

    Bicycle's Research and Development team is growing! View current US and UK openings here:

    Poništi
  20. 4. lis 2019.

    Our VP of Chemistry, Kevin McDonnell, gave a talk on our most advanced Bicycle® Toxin Conjugate, BT1718, at the 2019 Boulder Peptide Symposium last week. Here he is discussing the potential our BTCs have to target solid tumors more effectively than existing modalities.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·